References
- DelDuca V, Morningstar W A. Multiple myeloma associated with Progressive Multifocal Leukoencephalopathy. JAMA 1967; 199: 671–673
- Chang H, Sloan S, Li D, Keith S A. Multiple myeloma involving central nervous system: High frequency of chromosome 17p13.1(p53) deletions. Br J Haematol 2004; 127: 280–284
- Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 351: 1860–1873
- Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Richardson P G, Hideshima T, Munshi N C, Treon S P, Anderson K C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525–4530
- Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, Vivo A, Testoni N, Nicci C, Terragna C, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39
- Hauser S L, Goodin D S. Multiple Sclerosis and other demyelinating diseases. Harrison's principles of internal medicine16th ed., D L Kasper, et al. McGraw Hill, New York 2005; 2461–2471
- Garg R K. Posterior leukoencephalopathy syndrome. Postgrad Med J 2001; 77: 24–28
- Patrick F K, Yong S MA. Hamour and aine burns. Reversible posterior leukoencephalopathy in a patient with systemic sclerosis/systemic lupus erythematosus overlap syndrome. Nephrol Dial Transplant 2003; 18: 2660–2662
- Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Am J Neuroradiol 1998; 19: 415–417
- Delanty N, Vaughan C, Frucht S, Stubgen P. Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology 1997; 49: 686–689
- Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin M S, Lamy C, Mas J L, Caplan L R. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494–500
- Chodimella U, Munshi N C, Anaissie E, Desikan K R, Toor A, Badros A, Zangari M, Lim S, Barlogie B, Angtuaco E, Stringer W. REPLS (Reversible posterior leuko-encephalopathy syndrome) in a patient with newly diagnosed multiple myeloma—An unusual and previously unreported complication: A Case report. American Society of Hematology 41st Annual Meeting. New Orleans 1999, Abstract 4544
- Blade J, Samson D, Reece D, et al. Criteria for assessing disease response and progression in patients with multiple myeloma treated with high dose therapy and hematopoietic stem cell transplantation. Br J Hematol 1998; 102: 1115–1123
- McHugh S M, Rifkin I R, Deighton J, Wilson A B, Lachmann P J, Lockwood C M, Ewan P W. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160–167
- Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 2005; 106: 125–134